CAM
CSTL icon

Cresset Asset Management’s Castle Biosciences CSTL Stock Holding History

Cresset Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,405
Closed -$331K – 1743
2024
Q4 		$331K Sell
12,405
-2,325
-16% -$70.8K ﹤0.01% 1298
2024
Q3 		$420K Sell
14,730
-3,980
-21% -$101K ﹤0.01% 1628
2024
Q2 		$407K Buy
+18,710
New +$417K ﹤0.01% 1546
2021
Q2 		– Sell
-4,047
Closed -$277K – 1030
2021
Q1 		$277K Buy
+4,047
New +$304K ﹤0.01% 713

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cresset Asset Management's CSTL Position: Q1 2025 in Review

Cresset Asset Management sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 12,405 shares — an estimated $331K sold.

Cresset Asset Management first reported a position in CSTL in Q1 2021 and held it in 4 quarters. The position peaked at $420K in Q3 2024. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

  • Cresset Asset Management reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
  • Cresset Asset Management sold 12,405 Castle Biosciences shares in Q1 2025, an estimated $331K.
  • Cresset Asset Management first reported a position in Castle Biosciences in Q1 2021 and held it in 4 quarters.
  • Cresset Asset Management's Castle Biosciences position peaked at $420K in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Cresset Asset Management's 13F filing for Q1 2025, filed 13 May 2025.